IDO1 and atherosclerosis: The in vivo study using ApoE−/− mice showed that treatment with the IDO1 inhibitor 1-MT could significantly reverse the enhanced IDO1 activity and attenuate atherosclerosis progression in the early stage of atherosclerosis.